Top 10 Tech Companies To Invest In Right Now

Until recently, I would have avoided regional banks. However, the green shoots of the U.S. recovery are now sturdy enough that select financial institutions are showing highly bullish charts backed by strong fundamentals. Both the technicals and fundamentals tell me there is a good trading opportunity at hand.

According to the Federal Deposit Insurance Corp. (FDIC), the number of bank failures has dropped dramatically since June 2011. At this time two years ago, 48 banks had entered receivership. By this time in 2012, the number dropped to 31. So far this year, only 16 banks have failed -- one-third the number of failures compared with 2011.

 

Moreover, revenue and earnings prospects for select regional banks should continue to improve. For starters, the Federal Reserve's pledge to keep interest rates near record lows means low-cost loans for consumers, and that translates to strong loan demand at banks. According to Reuters, demand for commercial and industrial loans is on the rise. Continued economic growth should spur consumer spending and further increase demand for loans.

Top 10 Freight Companies To Buy For 2015: Taro Pharmaceutical Industries Ltd (TARO)

Taro Pharmaceutical Industries Ltd., incorporated in 1959, is a science-based pharmaceutical company. The Company develops manufactures, and markets prescription and over-the-counter (OTC) pharmaceutical products, primarily in the United States, Canada and Israel. The Company also develops and manufactures active pharmaceutical ingredients (APIs), primarily for use in its finished dosage form products. The Company�� primary areas of focus include pediatric creams and ointments, liquids, capsules and tablets, mainly in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories. The Company operates through three companies: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries (including indirect), Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The Company markets more than 180 pharmaceutical products in over 25 countries.

Taro Israel manufactures more than 160 finished dosage form pharmaceutical products for sale in Israel and for export. It produces APIs used in the manufacture of finished dosage form pharmaceutical products. It markets and distributes generic products in the local Israeli market. Taro Israel�� primary product lines include dermatology, prescription and OTC semi-solid products (creams, ointments and gels) and liquids; cardiology and neurology, prescription oral dosage products; oral analgesics, both prescription and OTC, and OTC oral and nasal sprays and ophthalmic products.

Taro Canada manufactures more than 70 finished dosage form pharmaceutical products for sale in Canada and for export. It markets and distributes generic products in the local Canadian market. Its product line includes dermatology: prescription and OTC semi-solid products (creams, ointments and gels) and liquids, cardiology, oncology, gastrointestinal and neurology: prescription oral and injects able dosage products, and allergy (antihistamine): OTC oral dosage products.

Taro U.S.A markets! and distributes generic products in the United States market. Its primary product lines include dermatology: prescription and OTC semi-solid products (creams, ointments and gels) and liquids, cardiology and neurology: prescription oral dosage products, and other prescription and OTC products.

The Company competes with Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, Pfizer/Wyeth, Valeant, Galderma, Merck/Schering-Plough, Teva Pharmaceuticals U.S.A., Mylan Laboratories, Perrigo Company, Ranbaxy Pharmaceuticals Inc., Sandoz Pharmaceuticals, Merck Canada Inc., Pfizer Canada Inc., Janssen Inc., Schering-Plough Canada, Novartis Pharmaceuticals Canada Inc., GlaxoSmithKline Inc., Bayer Inc., Bristol-Myers Squibb Canada, Apotex Inc., Teva Canada Limited, Mylan Pharmaceuticals ULC, Sandoz Canada Incorporated, Pharmascience Inc., Teva Pharmaceutical Industries Ltd., Perrigo Israel Pharmaceuticals Ltd., Dexxon Ltd., Rafa Laboratories Ltd., Bayer AG, Eli Lilly and Company, Merck & Co., Inc. and Pfizer Inc.

Advisors' Opinion:

• [By Rich Smith]

  Israeli drugmaker Taro Pharmaceutical Industries (NYSE: TARO  ) has a new CEO -- and a new Chairman of the Board, as well.

  On Thursday, Taro announced the imminent retirement of Interim Chief Executive Officer Mr. James Kedrowsk, who will be replaced August 1 by new permanent CEO Mr. Kalyanasundaram Subramanian ("Kal Sundaram"). Additionally, the company said that Dilip Shanghvi�has been appointed Chairman of its Board of Directors.

Top 10 Tech Companies To Invest In Right Now: Gilead Sciences Inc.(GILD)

Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amphotericin B liposome injection to treat invasive fungal infections; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa for the treatment of chronic angina; Vistide, an antiviral medication for the treatment of cytomegalovirus retinitis in patients with AIDS; and Cayston, an inhaled antibiotic used as a treatment to enhance respiratory systems. The company?s products also comprise Tamiflu, an oral antiviral for the treatment and prevention of influenza A and B; Macugen, an intravitreal injection for the treatment of neovascular a ge-related macular degeneration; and Lexiscan/Rapiscan, an injection used as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. Its products under the Phase III clinical trials consist of Cobicistat, a pharmacoenhancer that is under evaluation as a boosting agent for HIV medicines; Elvitegravir, an oral integrase inhibitor being evaluated as part of combination therapy for HIV; Integrase Single-Tablet, a ?Quad? regimen of elvitegravir, cobicistat, tenofovir disoproxil fumarate, and emtricitabine for the treatment of HIV/AIDS in treatment-naive patients; and Aztreonam for inhalation solution for the treatment of cystic fibrosis patients with Pseudomonas aeruginosa. The company?s Phase II clinical trials products comprise Cicletanine, Ranolazine, and Aztreonam, as well as GS 9190, GS 9256, and GS 9451. Its Phase I clinical trial products include GS 7340, GS 5885, GS 6620, GS 9620, and GS 6624. The company was founded in 1987 and is headquartered in Fost er City, California.

Advisors' Opinion:

• [By alicet236]

  Gilead Sciences Inc (GILD): Chairman and CEO John C Martin sold 140,625 Shares

  Chairman and CEO of Gilead Sciences Inc (GILD) John C Martin sold 140,625 shares on 02/03/2014 at an average price of $79.96. Gilead Sciences, Inc. was incorporated in Delaware on June 22, 1987. Gilead Sciences Inc has a market cap of $120.75 billion; its shares were traded at around $78.75 with a P/E ratio of 43.10 and P/S ratio of 12.34. Gilead Sciences Inc had an annual average earnings growth of 15.10% over the past 5 years.

Top 10 Tech Companies To Invest In Right Now: inContact Inc.(SAAS)

inContact, Inc. provides cloud-based contact center software services and network connectivity in the United States. Its solutions include inContact ACD, an automatic call distributor; inContact CTI, a computer telephony integration that integrates with customer data servers to provide agents pre-populated customer data; inContact IVR, an interactive voice response solution to create specialized call flows; and inContact Integrations for integration of various hardware and software solutions already in place at customer sites. The company also offers inContact ECHO that gathers the opinion of the customer and presents the analysis of the feedback directly to supervisors and agents; inContact Workforce Management, which forecasts demand, schedules workforce, analyzes and optimizes staffing, and reports real-time adherence in contact centers; inContact Quality Monitoring that provides insights into agent performance and customer satisfaction; and InContact Screen Recording, which provides compliance level screen recording functionality for voice channel interactions. In addition, it provides inContact eLearning that offers targeted, prioritized training, communications, and testing to the agent?s desktop during dips in call volumes; and inContact Network Connectivity, which includes time division multiplexing and voice over Internet protocol (VoIP) connectivity, and toll-free and local-number services. Further, inContact, Inc. offers professional services, as well as operates as a domestic and international long distance reseller and aggregator. The company was formerly known as UCN, Inc. and changed its name to inContact, Inc. in January 2009. inContact, Inc. was founded in 1994 and is headquartered in Salt Lake City, Utah.

Advisors' Opinion:

• [By Steve Symington]

  What:�Shares of inContact Inc. (NASDAQ: SAAS  ) rose more than 10% in Wednesday's early trading, and then gave back most of those gains to close up around 1% after the cloud contact center software provider released first-quarter results and announced an acquisition.

• [By James Miller Phd]

  Within the cloud computing applications, Salesforce has become a leading supplier and platform vendor, positioning itself in a strong position among other cloud application providers. Currently, through Sales Cloud, the company�� most popular product, it has succeeded in expanding its addressable market towards the purchase of Service Cloud as well. Providing different on-demand Software-as-a-Service (SaaS), such as the Sales Cloud, Service Cloud and Chatter applications, it allows customers to improve communication and sales to their respective customers. Moreover, it offers other platforms such as The Force.com Platform, or Heroku Platform, and developer tools like Database.com and The AppExchange, enabling its users to customize its applications.

• [By John Udovich]

  Small cap cloud contact software provider Five9 Inc (NASDAQ: FIVN) saw a small pop when it debuted in an IPO last Friday but its now trended back down to its debut price, meaning its worth taking a closer look at the stock along with some potential peers or benchmarks like Incontact Inc (NASDAQ: SAAS), eGain Corp (NASDAQ: EGAN) and LivePerson, Inc (NASDAQ: LPSN).

• [By jaggom]

  Approximately 35% of the respondents cited that the internal or private cloud projects still dominated cloud-related activity. The public cloud services such as infrastructure as a service (IaaS) and software as a service (SaaS) activity in enterprises also doubled in the range of 30% and 33% in just the past six months.

Top 10 Tech Companies To Invest In Right Now: Mobileye NV (MBLY)

Mobileye N.V., incorporated in 2001, designs and develops software and related technologies for camera-based advanced driver assistance systems (ADAS). The Company�� software algorithms and EyeQ system on a chip (SOC) perform detailed interpretations of the visual field in order to anticipate possible collisions with other vehicles, pedestrians, cyclists, animals, debris and other obstacles. Its products are also able to detect roadway markings such as lanes, road boundaries, barriers and similar items, as well as to identify and read traffic signs and traffic lights. The Company operates in two segments: the original equipment manufacturer (OEM) segment and the AM segment. The OEM segment supplies the software algorithms and EyeQ chip that are the core technology of the complete ADAS to the Tier 1 companies that are the system integrators for the automotive industry. In the AM segment, the Company sells a complete system, which includes its software algorithms and EyeQ chip, as well as the camera and other necessary components.

The complete system offers a variety of ADAS functions to end, including commercial fleet owners, fleet management system providers, new vehicle dealers and importers. Its software activity is divided into algorithms, which are the engines for extracting meaningful information from video; and application software. Its visual interpretation algorithms consist of road signs interpretation, object detection, range and time-to-contact (TTC) to targets, motion-based measurements, pattern recognition and lighting functions. Road signs interpretation consists of lane markings, curbs, road edge, barriers, and other information that allows high-level control systems to make sense of where the host car is located relative to the roadway. Object detection includes pattern recognition of vehicles, pedestrians and (large) animals for collision avoidance.

Motion-based measurements include the flow of pixels along a sequence of images due to camera motion provides! three-dimensional (3D) cues that are analyzed in many levels of the system. This analysis includes validation filters for object detection engines (vehicles, pedestrians, animals); separating moving objects from the background; detecting general (not model-based) objects; detecting debris (of at least 10 centimeters in height) from 50 meters away; reconstructing the road profile in order to detect bumps and potholes; generating a 3D map of the visual field using the principle of structure from motion, which is the process of estimating 3D structures from two dimensional (2D) image sequences, and which may be coupled with local motion signals, and fusing 3D and image pattern recognition to aid in scene interpretation, all of which will also support automated-driving functionality.

It has developed multiclass classifiers to enable traffic sign detection, traffic light detection and detection of other structures from the scene that are useful for supporting hands-free driving. Its adaptive high beam control (AHC) is enabled by a set of algorithms that read and interpret the spots of light in the night scene to determine when to turn on or off the high beam. Its aftermarket customers include commercial and governmental fleets, telematics providers and insurance companies. Its Tier 1 customers include Magna Electronics Inc., TRW Automotive Holdings Corp., Autoliv, Inc., Delphi Automotive Plc, Gentex Corporation, Kansei Corporation, Leopold Kostal GmbH and Mando Corporation as well as Bendix Corporation and Mobis Transportation Alternatives, Inc. working jointly with TRW.

Advisors' Opinion:

• [By WWW.DAILYFINANCE.COM]

  Mark Lennihan/APJack Ma is the founder of Alibaba. There has been no shortage of debutantes on Wall Street lately. Dozens of companies went public last quarter -- many of them names you know, or that you will know soon. These some of the more intriguing initial public offerings to come out of this past quarter. El Pollo Loco (LOCO) Fast casual has been the place to be for investing in the restaurant industry, and that helped pave the way for this California-based chain specializing in citrus-marinated chicken to go public in July at $15 a share. Investors won't be impressed by its slow yet calculated expansion. It had grown from 398 locations to just 401 in the year leading up to its IPO. However, El Pollo Loco's store-level performance has been impressive. It posted a 5.4 percent increase in comparable-restaurant sales in its first quarter as a public company. That is certainly better than the average fast-food or casual-dining chain out there, once again validating the fast-casual model, where chains offer the convenience of fast food but the quality of traditional casual-dining restaurants. Mobileye (MBLY) The push to develop self-driving cars is really getting traction, a fact that became even more apparent last week when Tesla (TSLA) showed off an updated sedan that uses a dozen sensors to do everything from adjusting speed in accordance with speed limit signs when it's on cruise control to switching lanes automatically when the sensors see an opening in traffic after the driver triggers the turn signal. But clever sensors notwithstanding, self-driving cars won't happen without serious software, and that's where Mobileye comes in. The Israeli company provides software and chips for camera-based advanced driver assistance systems. This will likely become a competitive market in the future, but for now Mobileye is seen as a leading pioneer in self-driving vehicles. Its share price has roughly doubled since it went public at $25 just two months ago. Re

• [By Jake Mann]

  One such name that does intrigue me is that of Mobileye NV (NYSE: MBLY).

  ...Ever see the cars in the movie I Robot? Well this is Sci Fi starting to come to life in a way. Think about it, who would have thought GPS would be standard in cars back 10-15 years ago. Now we are starting to cross the threshold of letting the car do the driving for you more and more?

Top 10 Tech Companies To Invest In Right Now: Enanta Pharmaceuticals Inc (ENTA)

Enanta Pharmaceuticals, Inc., incorporated on July 25, 1995, is a research and development-focused biotechnology company. The Company uses its chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field. The Company is discovering and developing novel inhibitors designed for use against the hepatitis C virus (HCV). These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes-protease (partnered with AbbVie, the former research-based pharmaceutical business of Abbott Laboratories), NS5A (partnered with Novartis) and nucleotide polymerase, as well as a host targeted antiviral (HTA) inhibitor class targeted against cyclophilin. ABT-450, discovered through its collaboration with AbbVie, is a protease inhibitor that has demonstrated in vitro potency against known resistant HCV mutants.

In Phase I studies, ABT-450 co-administered with ritonavir, a commonly used boosting agent to increase the blood concentrations of many protease inhibitors, was shown to be safe and well tolerated. Co-administration of ABT-450 with ritonavir, which it refers to together as ABT-450/r, has enabled once-daily dosing of ABT-450. Phase II studies have demonstrated the efficacy of ABT-450/r in patients with chronic HCV, and other interferon-free Phase II studies of ABT-450-containing regimens continue. AbbVie is developing a next-generation protease inhibitor discovered within the Enanta-AbbVie collaboration. EDP-239 is the NS5A inhibitor discovered by the Company. The Company also has a program to develop nucleotide inhibitors to HCV NS5B polymerase, which is another DAA mechanism considered to have a barrier to resistance. The Company�� Bicyclolide antibiotic product candidate is EDP-788, which it is developing for use as an intravenous drug in the hospital setting and for oral dosing in the home setting. EDP-788 is a prodrug, which means that it is inactive until it is converted in the body into an active compound. EDP-788 is! a water-soluble molecule which, when administered in preclinical models, is cleanly and rapidly converted into the active compound.

Advisors' Opinion:

• [By George Budwell]

  Normally, such strong efficacy results would be hailed as a major achievement. However, these results are actually less impressive than those by competing drug's developed by AbbVie (NYSE: ABBV  ) , Enanta Pharmaceuticals (NASDAQ: ENTA  ) and Gilead. Bristol-Myers' therapy also has a treatment duration double that of Gilead's drug Sovaldi for genotype 1 patients. So, while these results are impressive in their own right, the therapy's commercial prospects may be limited due to the presence of superior competitors in the market.�

• [By Ben Levisohn]

  The fundamentals of the biotech industry appear strong as measured by a robust list of ongoing and expected product launches. Large-cap biotech companies under our coverage (Alexion Pharmaceuticals, Amgen, Celgene, Gilead, Vertex Pharmaceuticals (VRTX)) all have ongoing or anticipated product launches in 2015. These launches…AbbVie (ABBV) /�Enanta Pharmaceuticals (ENTA) Viekirax + Exviera for hepatitis C…Other high-visibility launches include the expected launches of PCSK9 antibodies, evolocumab from�Amgen and alirocumab from Sanofi (SNY) / Regeneron (REGN) for high cholesterol, anticipated in 3Q:15. Although the expectation is for a slow ramp-up until cardiovascular outcome data (no later than 2017), the market is large enough to allow fast launches. For Celgene, Gilead, Medivation (MDVN) and Vertex, the launches are for their most important products; therefore the progress of the launches will be particularly important to watch.

• [By Sean Williams]

  The next big thing in treating hepatitis-C
  The other currently experimental therapy very likely to make it onto the FDA's desk before the midpoint of 2014 is AbbVie's (NYSE: ABBV  ) direct-acting antiviral combo drug. In similar fashion to Sovaldi, this DAA-combo therapy, which includes ABT-450 from Enanta Pharmaceuticals (NASDAQ: ENTA  ) , is running six confirmatory late-stage trials on various genotypes. There are, however, two primary differences between AbbVie's DAA-combo therapy and Sovaldi.

• [By James Fink]

  And lastly I'll go into healthcare, which is kind of a growth cyclical type name. It's partially defensive, partially growth. I think the more growth-oriented section of healthcare would be biotech, and right now, a very promising biotech stock is Enanta Pharmaceuticals. That's a NASDAQ stock; ticker symbol (ENTA).

Top 10 Tech Companies To Invest In Right Now: Receptos Inc (RCPT)

Receptos, Inc. (Receptos), incorporated on June 9, 2008, is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapeutics for immune disorders. The Company�� product candidates span three specialty disease areas. The Company�� lead asset, RPC1063, is being developed as an oral therapy for the treatment of relapsing multiple sclerosis (RMS) and inflammatory bowel disease (IBD). Its second asset, RPC4046, is being developed for the treatment of an allergic/immune-mediated disorder, eosinophilic esophagitis (EoE), which is an orphan disease. RPC1063 is an oral, once daily, selective and potent sphingosine 1-phosphate 1 receptor (S1P1R) modulator. RPC4046 is a monoclonal antibody selective to interleukin-13 (IL-13) and produced by recombinant deoxyribonucleic acid (DNA) technology.

As of December 31, 2012, RPC1063 was being tested in the Phase II portion of an accelerated design, randomized Phase II/III study for the treatment of RMS. In addition, Receptos has obtained special protocol assessment (SPA) agreement from the United States food and drug administration (FDA) on its clinical trial design for the planned Phase III portion of the Phase II/III study, as well as a second planned RMS Phase III study. RPC1063 is also being tested in a randomized Phase II study for the treatment of ulcerative colitis (UC), a gastrointestinal (GI) disea se.

As of December 31, 2012, the Company was enrolling a randomized Phase II study evaluating the ability of RPC1063 to induce clinical remission in patients with moderately-to-severely active UC called TOUCHSTONE. The Company�� second asset, RPC4046 for the treatment of EoE, builds upon its competencies in immunology and GI diseases. In-licensed from AbbVie Bahamas Ltd. and AbbVie Inc. (AbbVie) RPC4046 is a monoclonal antibody directed against the IL-13 target, which has been validated in Asthma, a predominantly allergic/immune-mediated disorder.

Advisors' Opinion:

• [By Garrett Cook]

  Receptos (NASDAQ: RCPT) shares shot up 38.62 percent to $93.90 after the company announced positive Phase 2 results for TOUCHSTONE Trial of RPC1063 in Ulcerative Colitis.

• [By Ben Levisohn]

  Yes, say the folks at Nomura, who recommend buying�Celgene (CELG), Receptos
  (RCPT), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), and Alexion Pharmaceuticals (ALXN), in that order. Analyst M. Ian Somaiya and team explain why:

Top 10 Tech Companies To Invest In Right Now: Procera Networks Inc (PKT)

Procera Networks, Inc. (Procera), incorporated in 2002, is a provider of intelligent policy enforcement (IPE) solutions that enables mobile and broadband network operators and entities managing private networks, including higher education institutions, businesses and government entities to gain control of their networks. The Company's products are marketed under the PacketLogic brand name. The Company sells its products through its direct sales force, resellers, distributors and systems integrators in the Americas, Asia Pacific and Europe. The Company�� three product lines include PacketLogic Subscriber Manager (PSM), PacketLogic Intelligence Center (PIC) and PacketLogic Real-Time Enforcement Platform (PRE). As of December 31, 2011, the Company had over 600 customers throughout North America, Europe and Asia. The Company's customers are mobile and broadband network operators. Broadband network operators include cable multiple system operators (MSOs), telecommunications companies, Internet service providers (ISPs) and private network operators.

The Company's IPE solution�� foundational element is its datastream recognition definition language (DRDL), DPI technology. DRDL facilitates a range of criteria to properly identify the application of each individual datastream. As of December 31, 2011, the DRDL database consisted of over 2,000 signatures. DRDL interconnects control and data sessions of protocols like file transfer protocol (FTP).The standard-syntax language of DRDL enables development of new signatures.

The Company delivers IPE solutions for networks operators, leveraging its DRDL DPI technology. The Company's IPE solutions support deep levels of awareness and a broad universe of applications, enabling richer services to be offered to consumers. The Company's analytics provide relevant business intelligence reports that enable broadband and mobile operators to understand consumer trends and respond to the dynamic application landscape.

The PSM integra! tes PacketLogic with network management and operation systems, including AAA, OSS, BSS, provisioning and policy managers. This integration enables policy enforcement, per-user tracking, also known as user awareness, as well as knowledge of where in the network the user connects (location awareness). It can also control roaming costs through automatic policy enforcement.

The PIC, with PacketLogic Report Studio provides the visualization of the application and subscriber intelligence gathered by deployed PacketLogic systems. Leveraging the subscriber and location awareness provided by the PSM and the application intelligence provided by the PRE, the PIC is able to present information to the network operator based on the behavior of their network. The intelligence can be presented in a multi-dimensional format, with per user, application, location, and device views available for business intelligence and planning. The PIC gives network managers access to relevant network traffic intelligence that enables network optimization, creation of appealing services and protection against malicious behavior.

The PRE utilize multiple hardware platforms that run the same operating software. It offers platforms through the different PacketLogic software modules: LiveView, Filtering, Traffic Shaping, and Statistics. The PacketLogic hardware platforms offer a range of configurations from the entry-level four mega bytes per second (Mbps) PL5600 through two giga bytes per second (Gbps) PL7720. The mid-range PL8720 is a 2RU unit with up to 10 Gbps throughput.

The Company competes with Allot Communications Ltd., Arbor Networks, Blue Coat Systems, Cisco Systems, Inc., Cloudshield Technologies, Sandvine Corporation, Alcatel-Lucent, Ericsson, Juniper Networks, Brocade Communications Systems, Huawei Technologies Company and Nokia Siemens.

Advisors' Opinion:

• [By Monica Gerson]

  Breaking news

  Starwood Hotels & Resorts Worldwide (NYSE: HOT) reported a gain in its third-quarter core earnings and lifted its full-year earnings forecast. To read the full news, click here. Procera Networks (NASDAQ: PKT) and Skyfire, a fully-owned subsidiary of Opera Software, today announced a joint solution and partnership to tackle the rapid growth of video traffic on global mobile networks, based on an open, scalable ICAP architecture. To read the full news, click here. R. R. Donnelley & Sons Company (NASDAQ: RRD) and Consolidated Graphics (NYSE: CGX) jointly announced today that they have signed a definitive agreement by which RR Donnelley will acquire Consolidated Graphics, a provider of digital and commercial printing, fulfillment services, print management and proprietary Internet-based technology solutions. To read the full news, click here. Dunkin' Brands Group (NASDAQ: DNKN) reported a 36% rise in its third-quarter income. To read the full news, click here.

  Posted-In: Jobless Claims JP Morgan US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets